For Head and Neck Cancer Awareness Month, Robert L. Ferris, MD, PhD, FACS, elaborated on the significant progress in the head and neck cancer space, as well as potentially practice-changing results that will come with emerging agents In an interview with Targeted Oncology™. He mentioned E3311 as one of the most practice-changing in the last 10 years because of the use of transoral robotic surgery permitting omission of chemotherapy and reduced-dose radiation for surgically treated HPV-positive patients. He highlighted the ongoing trial EA3191 involving immunotherapy.